Cash From Investing Activities - Devyser Diagnostics AB (STO:DVYSR) - Alpha Spread
D

Devyser Diagnostics AB
STO:DVYSR

Watchlist Manager
Devyser Diagnostics AB
STO:DVYSR
Watchlist
Price: 117.5 SEK 0.43% Market Closed
Market Cap: 1.9B SEK
Have any thoughts about
Devyser Diagnostics AB?
Write Note

Devyser Diagnostics AB
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Devyser Diagnostics AB
Cash from Investing Activities Peer Comparison

Comparables:
BIOG B
BONEX
VITR
SOBI
BIOA B

Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
D
Devyser Diagnostics AB
STO:DVYSR
Cash from Investing Activities
-kr32m
CAGR 3-Years
-89%
CAGR 5-Years
-45%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Cash from Investing Activities
-kr50.9m
CAGR 3-Years
-47%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Cash from Investing Activities
-kr8.3m
CAGR 3-Years
-62%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Cash from Investing Activities
-kr325m
CAGR 3-Years
-187%
CAGR 5-Years
-8%
CAGR 10-Years
-43%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Cash from Investing Activities
-kr1.7B
CAGR 3-Years
25%
CAGR 5-Years
29%
CAGR 10-Years
-42%
BioArctic AB
STO:BIOA B
Cash from Investing Activities
-kr507.5m
CAGR 3-Years
-243%
CAGR 5-Years
-178%
CAGR 10-Years
N/A

See Also

What is Devyser Diagnostics AB's Cash from Investing Activities?
Cash from Investing Activities
-32m SEK

Based on the financial report for Dec 31, 2023, Devyser Diagnostics AB's Cash from Investing Activities amounts to -32m SEK.

What is Devyser Diagnostics AB's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
-45%

Over the last year, the Cash from Investing Activities growth was -34%. The average annual Cash from Investing Activities growth rates for Devyser Diagnostics AB have been -89% over the past three years , -45% over the past five years .

Back to Top